Pancreatic Cancer Research

ResearcherUniversity of CambridgeActive in the last 2 years

Gianluca Mucciolo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7296-0217; OpenAlex author ID A5011920450. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 3 papers · 2025: 2 papers · 2026: 4 papers

Papers 11

  1. Multi-stromal organoid co-culture modelling reveals epithelial-fibroblast heterogeneity in pancreatic cancer and pancreatitis. Co-author DOI 10.1038/s41556-026-02057-w↗
  2. Lung Metastases in Pancreatic Cancer: Timing Their First Breath. Co-author DOI 10.1158/0008-5472.can-25-4465↗
  3. Cross-species graph-embedding unmasks the ageing microenvironment as a key determinant of pancreatic cancer malignant cell biology and therapy response Co-author DOI 10.64898/2026.02.02.703350↗
  4. TGF-β- and IL-1-dependent fibroblast states differentially shape pancreatic cancer microenvironments and metastasis Co-author DOI 10.64898/2026.09.08.750042↗
  5. The absence of IL17A favours cytotoxic cell function and improves antigen-specific immunotherapies in pancreatic adenocarcinoma. Co-author DOI 10.1002/ctm2.70442↗
  6. SMAD4 and KRAS Status Shapes Cancer Cell-Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-2330↗
  7. EGFR-activated myofibroblasts promote metastasis of pancreatic cancer. Co-author DOI 10.1016/j.ccell.2023.12.002↗
  8. Cancer-Associated Fibroblasts: From Spectators to Protagonists in Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-24-2448↗
  9. PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer. First author DOI 10.1186/s13046-024-03080-1↗
  10. IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions. Co-author DOI 10.1073/pnas.2020395118↗
  11. The dark side of immunotherapy: pancreatic cancer. Co-author DOI 10.20517/cdr.2020.13↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Giulia Biffi · 7 shared papers, 2024–2026 · strength 2.06
  2. Joaquín Araos Henríquez · 5 shared papers, 2024–2026 · strength 1.07
  3. Priscilla S.W. Cheng · 5 shared papers, 2024–2026 · strength 1.07
  4. Eloise G. Lloyd · 5 shared papers, 2024–2026 · strength 1.07
  5. Wenlong Li · 4 shared papers, 2024–2026 · strength 1.01
  6. Rebecca J. Brais · 3 shared papers, 2025–2026 · strength 0.65
  7. Cecilia Roux · 4 shared papers, 2020–2025 · strength 0.62
  8. Paola Cappello · 4 shared papers, 2020–2025 · strength 0.62
  9. Francesco Novelli · 4 shared papers, 2020–2025 · strength 0.62
  10. Silvia Brugiapaglia · 3 shared papers, 2020–2025 · strength 0.52
  11. Claudia Curcio · 3 shared papers, 2021–2025 · strength 0.49
  12. Debasmita Mukherjee · 2 shared papers, 2026 · strength 0.46
  13. Bristi Basu · 1 shared paper, 2026 · strength 0.22
  14. Giorgia Tiberi · 1 shared paper, 2025 · strength 0.20
  15. Vincenzo Corbo · 1 shared paper, 2025 · strength 0.20
  16. Giulia Adriani · 1 shared paper, 2025 · strength 0.20
  17. Lisa Veghini · 1 shared paper, 2025 · strength 0.20
  18. Judith A. Varner · 1 shared paper, 2024 · strength 0.18
  19. Michela Capello · 1 shared paper, 2021 · strength 0.10
  20. Rita Teresa Lawlor · 1 shared paper, 2021 · strength 0.10
  21. Aldo Scarpa Scarpa · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.